These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 35100894)

  • 1. Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study.
    van Wifferen F; de Jonge L; Worthington J; Greuter MJE; Lew JB; Nadeau C; van den Puttelaar R; Feletto E; Yong JHE; Lansdorp-Vogelaar I; Canfell K; Coupé VMH;
    J Med Screen; 2022 Jun; 29(2):72-83. PubMed ID: 35100894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study.
    de Jonge L; Worthington J; van Wifferen F; Iragorri N; Peterse EFP; Lew JB; Greuter MJE; Smith HA; Feletto E; Yong JHE; Canfell K; Coupé VMH; Lansdorp-Vogelaar I;
    Lancet Gastroenterol Hepatol; 2021 Apr; 6(4):304-314. PubMed ID: 33548185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
    Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
    Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prioritisation by FIT to mitigate the impact of delays in the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling study.
    Loveday C; Sud A; Jones ME; Broggio J; Scott S; Gronthound F; Torr B; Garrett A; Nicol DL; Jhanji S; Boyce SA; Williams M; Barry C; Riboli E; Kipps E; McFerran E; Muller DC; Lyratzopoulos G; Lawler M; Abulafi M; Houlston RS; Turnbull C
    Gut; 2021 Jun; 70(6):1053-1060. PubMed ID: 32855306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling optimal use of temporarily restricted colonoscopy capacity in a FIT-based CRC screening program: Application during the COVID-19 pandemic.
    de Jonge L; van de Schootbrugge-Vandermeer HJ; Breekveldt ECH; Spaander MCW; van Vuuren HJ; van Kemenade FJ; Dekker E; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
    PLoS One; 2022; 17(6):e0270223. PubMed ID: 35749423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling the impact of the coronavirus pandemic on bowel cancer screening outcomes in England: A decision analysis to prepare for future screening disruption.
    Mandrik O; Chilcott J; Thomas C
    Prev Med; 2022 Jul; 160():107076. PubMed ID: 35526674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential global loss of life expected due to COVID-19 disruptions to organised colorectal cancer screening.
    Worthington J; van Wifferen F; Sun Z; de Jonge L; Lew JB; Greuter MJE; van den Puttelaar R; Feletto E; Lansdorp-Vogelaar I; Coupé VMH; Ein Yong JH; Canfell K;
    EClinicalMedicine; 2023 Aug; 62():102081. PubMed ID: 37538541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact and Recovery from COVID-19-Related Disruptions in Colorectal Cancer Screening and Care in the US: A Scenario Analysis.
    van den Puttelaar R; Lansdorp-Vogelaar I; Hahn AI; Rutter CM; Levin TR; Zauber AG; Meester RGS
    Cancer Epidemiol Biomarkers Prev; 2023 Jan; 32(1):22-29. PubMed ID: 36215205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the COVID-19 Pandemic on Fecal Immunochemical Testing, Colonoscopy Services, and Colorectal Neoplasia Detection in a Large United States Community-based Population.
    Lee JK; Lam AY; Jensen CD; Marks AR; Badalov J; Layefsky E; Kao K; Ho NJ; Schottinger JE; Ghai NR; Carlson CM; Halm EA; Green B; Li D; Corley DA; Levin TR
    Gastroenterology; 2022 Sep; 163(3):723-731.e6. PubMed ID: 35580655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A delay in the diagnosis of colorectal cancer screened by fecal immunochemical tests during the COVID-19 pandemic: a longitudinal cohort study.
    Ishibashi F; Shida D; Suzuki S; Nagai M; Mochida K; Morishita T
    Int J Colorectal Dis; 2022 Dec; 37(12):2543-2546. PubMed ID: 36383225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Faecal immunochemical test outside colorectal cancer screening?
    Pin-Vieito N; Puga M; Fernández-de-Castro D; Cubiella J
    World J Gastroenterol; 2021 Oct; 27(38):6415-6429. PubMed ID: 34720531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Évaluation de la gravité du cancer colorectal dépisté dans le contexte de la crise sanitaire liée au COVID19 en région Ile-de-France].
    Koïvogui A; Abihsera G; Le Trong T; Ait-Hadad H; Bernoux A; Delattre H; Vincelet C; Caroll R; Nicolet J
    Rev Epidemiol Sante Publique; 2023 Oct; 71(5):102124. PubMed ID: 37451076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme.
    Peng SM; Hsu WF; Wang YW; Lin LJ; Yen AM; Chen LS; Lee YC; Wu MS; Chen TH; Chiu HM
    Gut; 2021 Jul; 70(7):1318-1324. PubMed ID: 32989019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of delayed screening colonoscopies during the COVID-19 pandemic on clinical outcomes.
    McCarthy R; Mooney T; Fitzpatrick P; Kennedy RA; Coffey H; Sheedy M; MacMathúna P
    Cancer Epidemiol; 2024 Oct; 92():102629. PubMed ID: 39088893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact on clinical outcomes and healthcare resources from discontinuing colonoscopy surveillance subsequent to low-risk adenoma removal: A simulation study using the OncoSim-Colorectal model.
    Steer KJ; Sun Z; Sadowski DC; Yong JHE; Coldman A; Nemecek N; Yang H
    J Med Screen; 2024 Jun; 31(2):78-84. PubMed ID: 37728194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimising colorectal cancer screening in Shanghai, China: a modelling study.
    Cenin D; Li P; Wang J; de Jonge L; Yan B; Tao S; Lansdorp-Vogelaar I
    BMJ Open; 2022 May; 12(5):e048156. PubMed ID: 35577474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
    Tinmouth J; Lansdorp-Vogelaar I; Allison JE
    Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term impact of the COVID-19 pandemic on a population-based screening program for colorectal cancer in Catalonia (Spain).
    Vives N; Binefa G; Vidal C; Milà N; Muñoz R; Guardiola V; Rial O; Garcia M
    Prev Med; 2022 Feb; 155():106929. PubMed ID: 34954239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening.
    Grobbee EJ; van der Vlugt M; van Vuuren AJ; Stroobants AK; Mallant-Hent RC; Lansdorp-Vogelaar I; Bossuyt PMM; Kuipers EJ; Dekker E; Spaander MCW
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):667-675.e1. PubMed ID: 31419575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.